- Home
- MIRM vs QS Comparison
MIRM vs QS Comparison
Compare MIRM & QS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- QS
- Stock Information
- Founded
- MIRM 2018
- QS 2010
- Country
- MIRM United States
- QS United States
- Employees
- MIRM 334
- QS N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- QS Auto Parts:O.E.M.
- Sector
- MIRM Health Care
- QS Consumer Discretionary
- Exchange
- MIRM Nasdaq
- QS Nasdaq
- Market Cap
- MIRM 2.2B
- QS 2.2B
- IPO Year
- MIRM 2019
- QS N/A
- Fundamental
- Price
- MIRM $44.86
- QS $3.91
- Analyst Decision
- MIRM Strong Buy
- QS Sell
- Analyst Count
- MIRM 12
- QS 7
- Target Price
- MIRM $63.17
- QS $5.19
- AVG Volume (30 Days)
- MIRM 397.1K
- QS 13.5M
- Earning Date
- MIRM 05-07-2025
- QS 07-23-2025
- Dividend Yield
- MIRM N/A
- QS N/A
- EPS Growth
- MIRM N/A
- QS N/A
- EPS
- MIRM N/A
- QS N/A
- Revenue
- MIRM $379,251,000.00
- QS N/A
- Revenue This Year
- MIRM $33.98
- QS N/A
- Revenue Next Year
- MIRM $16.19
- QS N/A
- P/E Ratio
- MIRM N/A
- QS N/A
- Revenue Growth
- MIRM 69.31
- QS N/A
- 52 Week Low
- MIRM $23.83
- QS $3.40
- 52 Week High
- MIRM $54.23
- QS $9.52
- Technical
- Relative Strength Index (RSI)
- MIRM 56.31
- QS 45.64
- Support Level
- MIRM $43.30
- QS $3.80
- Resistance Level
- MIRM $44.57
- QS $4.37
- Average True Range (ATR)
- MIRM 1.20
- QS 0.24
- MACD
- MIRM -0.05
- QS -0.02
- Stochastic Oscillator
- MIRM 54.57
- QS 10.79
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.